Myasthenia Gravis Disease Treatment Market Predicts $2.32 billion & 7.00% CAGR by 2032

Myasthenia Gravis Disease Treatment Market Size Worth $2.32 Billion By 2032 | CAGR: 7.00%

The global myasthenia gravis disease treatment market size is expected to reach USD 2.32 billion by 2032, according to a new study by Polaris Market Research. The report Myasthenia Gravis Disease Market Share, Size, Trends, Industry Analysis Report, By Drug Class (IVIg, Monoclonal Antibodies, Immunosuppressants, Cholinesterase Inhibitors, Corticosteroids); By Diagnosis, By Treatment, By Distribution Channel; By Region; Segment Forecast, 2024 - 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Myasthenia gravis is an autoimmune neuromuscular disorder that causes muscle weakness and fatigue due to the immune system attacking the connection between nerves and muscles.

The market for treating Myasthenia Gravis (MG) has been growing steadily in recent years due to several factors. There has been an increase in the number of diagnoses, better understanding of the disease, and advancements in treatment options. Pharmaceutical companies have also invested in research and development to introduce innovative therapies that offer more effectiveness and fewer side effects. With the emergence of biologics and targeted therapies, the demand for safer and more efficient treatments is expected to continue driving the growth of the global MG treatment market.

The COVID-19 pandemic had a significant impact on the Myasthenia Gravis (MG) disease market. MG faced challenges due to the healthcare system's focus on COVID-19 patients, causing delays in diagnosis and treatment. However, the pandemic accelerated the use of telemedicine and remote monitoring, which provided crucial tools for MG patients to consult with healthcare providers while minimizing virus exposure. The pharmaceutical industry continued to develop novel therapies for MG despite disruptions, offering hope for improved treatment options.

Do you have any questions? Would you like to request a sample or make an inquiry before purchasing this report? Simply click the link below:

Additionally, a study published in the National Library of Medicine in June 2021 highlighted the significant impact of coronary artery disease (CAD) on global health. CAD alone is responsible for approximately 610,000 deaths annually, accounting for an estimated one in four deaths and making it the foremost cause of mortality in the United States. With the incidence of CAD rising, there is a growing demand for effective coronary stent devices to address this pressing medical need. Consequently, this factor is projected to drive the demand for coronary stents throughout the forecast period.

Myasthenia Gravis Disease Market Report Highlights

  • In 2022, the IVIg segment held the largest revenue share in the myasthenia gravis disease market. Intravenous Immunoglobulin (IVIg) treatment involves the infusion of immunoglobulin antibodies obtained from healthy donors. This medical procedure has been found to be highly effective in temporarily regulating the immune system and managing the symptoms of Myasthenia Gravis (MG).
  • The hospital segment accounted for the highest market share during the forecast period. Hospital pharmacies play a vital role in managing Myasthenia Gravis (MG) through the distribution and application of various medications. As MG cases increase, more patients seek treatment in hospitals, leading to a higher demand for MG-specific drugs in hospital pharmacies.
  • In 2022, North America dominated the largest market. Myasthenia gravis (MG) exhibits a significant prevalence in North America, positioning it as a key player in the landscape of treatment. The region's robust healthcare infrastructure facilitates the identification and management of a substantial number of MG cases, drawing the interest of pharmaceutical firms and researchers alike. Furthermore, the resilient healthcare reimbursement framework effectively extends coverage to numerous costly MG treatments, enhancing their accessibility for patients and promoting prompt intervention.
  • The Asia-Pacific region accounted for the fastest growth in the myasthenia disease treatment market. The market's growth is driven by various factors, notably the concerted efforts of both public and private entities. These endeavors primarily focus on advancing and distributing effective treatments for neuromuscular disorders. Moreover, the market's expansion is fueled by increasing public awareness of neuromuscular conditions, supported by educational campaigns and information dissemination initiatives.
  • The global key market players include AbbVie Inc., Alexion Pharmaceuticals, Inc., Bausch Health Companies Inc., Bristol-Myers Squibb Company, Grifols, S.A., Mylan N.V., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Roche Holdings AG, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd.

Polaris Market Research has segmented the myasthenia disease treatment market report based on drug class, diagnosis, treatment, distribution channel, and region:

Myasthenia Gravis Disease Treatment, Drug Class Outlook (Revenue - USD Billion, 2019 - 2032)

  • IVIg
  • Monoclonal Antibodies
  • Immunosuppressants
  • Cholinesterase Inhibitors
  • Corticosteroids

Myasthenia Gravis Disease Treatment, Diagnosis Outlook (Revenue - USD Billion, 2019 - 2032)

  • Blood Tests
  • Electrodiagnosis
  • Edrophonium Test

Myasthenia Gravis Disease Treatment, Treatment Outlook (Revenue - USD Billion, 2019 - 2032)

  • Surgery
  • Medication
  • HSCT

Myasthenia Gravis Disease Treatment, Distribution Channel Outlook (Revenue - USD Billion, 2019 - 2032)

  • Online Pharmacies
  • Hospital Pharmacies
  • Retail Pharmacies

Myasthenia Gravis Disease Treatment, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Myasthenia Gravis Disease Treatment Market Report Scope

Report Attributes


Market size value in 2024

USD 1.35 billion

Revenue forecast in 2032

USD 2.32 billion


7.00% from 2024 – 2032

Base year


Historical data

2019 – 2022

Forecast period

2024 – 2032

Quantitative units

Revenue in USD billion and CAGR from 2024 to 2032

Segments Covered

By Drug Class, By Diagnosis, By Treatment, By Distribution Channel, By Region

Regional scope

North America, Europe, Asia Pacific, Latin America; Middle East & Africa


Report customization as per your requirements with respect to countries, region and segmentation.

For Specific Research Requirements

Request for Customized Report

License and Pricing

Purchase Report Sections

  • Regional analysis
  • Segmentation analysis
  • Industry outlook
  • Competitive landscape
Request for Discount Pricing